Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

Stock Information for Rezolute Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rezolute Inc.

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Rezolute to Participate in Upcoming Investor Conferences
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Rezolute, Inc. Investigated by the Portnoy Law Firm
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Launches Investigation into Rezolute

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.